使用 CRISPR/Cas9 编辑甲状腺癌细胞系。

Using CRISPR/Cas9 to Edit a Thyroid Cancer Cell Line.

机构信息

Department of Cell and Developmental Biology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil.

出版信息

Adv Exp Med Biol. 2023;1429:73-84. doi: 10.1007/978-3-031-33325-5_5.

DOI:10.1007/978-3-031-33325-5_5

PMID:37486517

Abstract

Thyroid cancer is the most prevalent endocrine malignancy, comprising multiple types of cancer, with distinct clinical-pathological characteristics. The oncogenesis of thyroid cancer is related to genetic alterations in MAPK signaling that induce proliferation and modulate noncoding genes, such as microRNAs and long noncoding RNAs. In this context, CRISPR/Cas9 emerges as a potential tool to modify gene sequence and modulate gene expression in thyroid cancer cell lines. In this chapter, we explore some of the current studies in which researchers have applied CRISPR/Cas9 in vitro to investigate thyroid cancer biology (Fig. 5.1).

摘要

甲状腺癌是最常见的内分泌恶性肿瘤，包括多种癌症类型，具有不同的临床病理特征。甲状腺癌的发生与 MAPK 信号通路中的基因突变有关，这些突变可诱导细胞增殖并调节非编码基因，如 microRNAs 和长非编码 RNA。在这种情况下，CRISPR/Cas9 成为一种潜在的工具，可以修饰甲状腺癌细胞系中的基因序列并调节基因表达。在本章中，我们探讨了一些当前的研究，其中研究人员在体外应用 CRISPR/Cas9 来研究甲状腺癌生物学（图 5.1）。